Premium
Cancer Therapy: Injectable Supramolecular Hydrogels as Delivery Agents of Bcl‐2 Conversion Gene for the Effective Shrinkage of Therapeutic Resistance Tumors (Adv. Healthcare Mater. 11/2017)
Author(s) -
Liu Xuan,
Chen Xiaohong,
Chua Ming Xuan,
Li Zibiao,
Loh Xian Jun,
Wu YunLong
Publication year - 2017
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201770053
Subject(s) - self healing hydrogels , gene delivery , in vivo , cancer research , genetic enhancement , materials science , cancer , medicine , nanotechnology , chemistry , gene , biology , microbiology and biotechnology , biochemistry , polymer chemistry
In article number 1700159 , Zibiao Li, Xian Jun Loh, Yun‐Long Wu, and co‐workers design injectable MPEG‐PCL‐PEI/α‐CD based supramolecular hydrogels that possess good sustained release ability of Bcl‐2 conversion genes in form of polyplex, to effectively inhibit in vivo tumor growth. This long term “enemy to friend” strategy will benefit various applications, including on‐demand gene delivery and personalized medicine.